Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor David Schiff, MD, will present clinical trial data at the European Association of Neurosurgical Societies’ annual meeting in Tel Aviv, Israel, November 11-14, 2013. His poster, entitled “Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in recurrent high-grade gliomas: An Adult Brain Tumor Consortium Study (ABTC1101),” highlights the design and progress of the dose escalation trial evaluating the safety and pharmacokinetics of lead compound mibefradil sequentially administered with temozolomide – a proprietary approach called Interlaced Therapy™.
Help employers find you! Check out all the jobs and post your resume.
